Efficacy of Deucravacitinib and Guselkumab in a Psoriasis Patient with Multiple Biologic Failures: A Case Report

This case highlights the successful use of combination therapy in a 69-year-old patient with recalcitrant psoriasis, achieving clinically significant improvement with deucravacitinib and guselkumab after multiple biologic failures. Deucravacitinib’s selective TYK2 inhibition, combined with guselkumab’s IL-23 blockade, may have provided enhanced suppression of the Th17 inflammatory pathway. Further research is needed to define the efficacy and tolerance of such combination regimens in severe, difficult-to-treat psoriasis cases.